Here are the S-3 shelf registrations from Citius Pharmaceuticals Inc. (CTXR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow CTXR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTXR filings page.
Citius Pharmaceuticals registers up to 5,431,473 shares of common stock issuable upon exercise of warrants. This preliminary prospectus covers (i) up to 5,076,143 shares issuable upon exercise of Common Warrants and (ii) up to 355,330 shares issuable upon exercise of Placement Agent Warrants, offered for resale by the selling stockholders. The company will not receive proceeds from resales, but could receive up to $4,803,000.81 in the aggregate if all warrants are exercised for cash; such proceeds are allocated to working capital. The prospectus discloses Nasdaq bid-price noncompliance notice and recent financings including a registered direct offering that raised approximately $4.5 million net proceeds.